Compare ACNB & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACNB | DCTH |
|---|---|---|
| Founded | 1857 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 659.3M | 578.4M |
| IPO Year | 1994 | 2015 |
| Metric | ACNB | DCTH |
|---|---|---|
| Price | $66.76 | $20.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $70.33 | $28.60 |
| AVG Volume (30 Days) | 44.8K | ★ 653.4K |
| Earning Date | 10-22-2026 | 11-09-2026 |
| Dividend Yield | ★ 2.51% | N/A |
| EPS Growth | N/A | ★ 107.53 |
| EPS | ★ 4.36 | 0.21 |
| Revenue | ★ $191,821,000.00 | N/A |
| Revenue This Year | $11.18 | $36.66 |
| Revenue Next Year | $2.76 | $20.12 |
| P/E Ratio | ★ $15.28 | $101.90 |
| Revenue Growth | ★ 45.10 | N/A |
| 52 Week Low | $44.62 | $8.12 |
| 52 Week High | $68.85 | $22.51 |
| Indicator | ACNB | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 59.80 | 72.77 |
| Support Level | $62.14 | $10.76 |
| Resistance Level | $68.23 | N/A |
| Average True Range (ATR) | 1.42 | 1.10 |
| MACD | 0.07 | 0.81 |
| Stochastic Oscillator | 53.71 | 79.30 |
ACNB Corp is the financial holding company. Through its wholly-owned subsidiaries, it provides a full range of retail and commercial financial services in Pennsylvania and Maryland through its network of community banking offices. It also provides property, casualty, health, life and disability insurance serving personal and commercial clients through offices in Westminster, Maryland, and Gettysburg, Pennsylvania and is licensed to do business. The corporation has two reporting segments; the Banking segment which generates the majority of the revenue from banking and wealth management services, including trust and retail brokerage; and ACNB Insurance Services segment which offers a broad range of property and casualty, life and health insurance to both commercial and individual clients.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.